The US Food and Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India Limited for Metformin Extended Release (ER) tablets 500 mg and 750 mg.
The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Glucophage XR tablets of Bristol Myers Squibb. Granules India Ltd intends to commercialize this product shortly.
Shares of GRANULES INDIA LTD. was last trading in BSE at Rs.108.4 as compared to the previous close of Rs. 110. The total number of shares traded during the day was 98448 in over 842 trades.
The stock hit an intraday high of Rs. 111.3 and intraday low of 107. The net turnover during the day was Rs. 10634860.